Renal dysfunction following ileal conduit urinary diversions after radical cystectomy: a five year follow-up study


  • Balaganur Sathyanarayana Department of Urology,Dr Pinnamaneni Siddhartha Institute of Medical Sciences and Research Foundation,Gannavaram,Andhra Pradesh,India
  • Vasantha Rao Periketi Consultant Urologist,Apollo Hospital,Hyderabad,Telangana,India



Renal function, Ileal conduit urinary diversion, Radical cystectomy


Background: Ileal conduit (IC) is the most commonly performed urinary diversions (UD) contributing 33-72 % of all types of UD with. Ileal conduits are relatively easy and quick to create, with a low rate of surgical complications. However, there is an incidence of renal deterioration was comparatively high following radical cystectomy, irrespective of the type of UD. To this purpose, we evaluated the post-operative renal function and non-surgical risk factors for loss of renal function in patients who underwent radical cystectomy with ICUD.

Methods: In this retrospective single institutional study, we evaluated risk factors for loss of renal function in 45 patients who had undergone radical cystectomy with ileal conduit as the sole form of urinary diversion. Renal function was calculated based on e-GFR. Analysed risk factors were age, gender, hypertension, diabetes, preoperative renal function, the post-operative occurrence of acute pyelonephritis and chemotherapy.

Results: There were 30 males and 15 female patients; the median follow-up was 36 months (3-90 months). The mean e-GFR before surgery was 74.2 (22.7-143.7) ml/min/1.73 m2, and it was 58.6 (8.2-140.9) ml/min/1.73 m2 after surgery, at last, follow up. Five-year renal deterioration free interval was 63.8%. Multivariate analysis showed that post-operative occurrence of acute pyelonephritis (p=0.0003) and treatment with chemotherapy (p <0.000) were significant risk factors for loss of renal function.

Conclusions: In our study, 13/45 (28.8%) patients demonstrated a reduction in renal function during the follow-up period. Postoperative episodes of acute pyelonephritis and treatment with chemotherapy were found to be significant risk factors. 


Hautmann RE, Abol-Enein H, Hafez K, Haro I, Mansson W, Mills RD. Urinary diversion. Urology. 2007;69(1):17-49.

Siddiqui KM, Izawa JI. Ileal conduit: standard urinary diversion for elderly patients undergoing radical cystectomy. World journal of urology. 2016;34(1):19-24.

Huang Y, Pan X, Zhou Q, Huang H, Li L, Cui X. Quality-of-life outcomes and unmet needs between ileal conduit and orthotopic ileal neobladder after radical cystectomy in a Chinese population: a 2-to-1 matched-pair analysis. BMC Urology. 2015;15:117.

Hatakeyama S, Koie T, Narita T, Hosogoe S, Yamamoto H, Tobisawa Y. Renal function outcomes and risk factors for stage 3B chronic kidney disease after urinary diversion in patients with muscle-invasive bladder cancer. PloS one. 2016;11(2):e0149544.

Madersbacher S, Schmidt J, Eberle JM, Thoeny HC, Burkhard F, Hochreiter W. Long-term outcome of ileal conduit diversion. J Urol. 2003;169(3):985-90.

Samuel JD, Bhatt RI, Montague RJ, Clarke NW, Ramani VA. The natural history of postoperative renal function in patients undergoing ileal conduit diversion for cancer measured using serial isotopic glomerular filtration rate and 99m technetium-mercapto acetyltriglycine renography. The Journal of urology. 2006;176(6):2518-22.

Nishikawa M, Miyake H, Yamashita M, Inoue TA, Fujisawa M. Long-term changes in renal function outcomes following radical cystectomy and urinary diversion. International journal of clinical oncology. 2014;19(6):1105-11.

Kristjansson A, Wallin L, Mansson W. Renal function up to 16 years after conduit (refluxing or anti-reflux anastomosis) or continent urinary diversion. Glomerular filtration rate and patency of uretero-intestinal anastomosis. Br J Urol. 1995;76(5):539-45.

Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N, Herr HW. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer. 1989;64(12):2448-58.

Sternberg CN, Yagoda A, Scher HI, Watson RC, Herr HW, Morse MJ. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol. 1988;139(3):461-9.






Original Research Articles